1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole
• 英文别名: [5-fluoro-3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)indol-1-yl]-phenylmethanone
• 化学式: C₂₁H₁₉FN₂O
• 分子量: 334.4
• InChiKey: GDCXPPXOHLRQSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯甲酰氯 、 5-氟-3-(1-甲基-1,2,3,6-四氢-4-吡啶基)-1H-吲哚 、 三乙胺 在 4-二甲氨基吡啶 水 、 二氯甲烷 、 Brine 、 Sodium sulfate-III 、 silica gel 、 氨 、 氯仿 作用下， 以 二氯甲烷 为溶剂， 以yielded 1-benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (27.8 mg, 39%, HRMS-FAB+ for C21H20N2OF calculated MH+ : 335.15598; found: 335.15457)的产率得到1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole
  参考文献：
  名称：

  Piperidine-indole compounds having 5-HT.sub.6 affinity

  摘要：

  本文描述了对5-HT.sub.6受体具有亲和力的化合物，其具有以下通式：其中：R.sup.1选自H和C.sub.1-4烷基的群组；R.sup.2选自H、C.sub.1-4烷基和苄基的群组；——表示单键或双键；R.sup.3选自COR.sup.5和SO.sub.2R.sup.5的群组；R.sup.4a选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sup.4b选自H、羟基、卤素、C.sub.3-7环烷氧基、C.sub.1-4烷氧基、C.sub.1-4烷基、苄氧基、苯氧基、三氟甲基、三氟甲氧基和乙烯基的群组；R.sup.4c选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sub.4d选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sup.5选自苯基、吡啶基、噻吩基、喹啉基和萘基，其中可以选用1-4个从C.sub.1-4烷氧基、C.sub.1-4烷基、卤素、硝基、三氟甲基、三氟甲氧基、1,2-亚甲二氧基、C.sub.1-4烷基羰基、C.sub.1-4烷氧基羰基和C.sub.1-4烷基S--中选择的取代基。还描述了这些化合物作为药物治疗5-HT.sub.6受体受到抑制的疾病，如精神分裂症的用途。

  公开号：

  US06133287A1

文献信息

• PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY
  申请人：NPS Allelix Corp.

  公开号：EP1173432B9

  公开（公告）日：2008-10-15
• US6133287A
  申请人：——

  公开号：US6133287A

  公开（公告）日：2000-10-17
• [EN] PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY<br/>[FR] COMPOSES PIPERIDINE-INDOL AYANT UNE AFFINITE AVEC 5-HT6
  申请人：ALLELIX BIOPHARMA

  公开号：WO2000063203A1

  公开（公告）日：2000-10-26

  Described herein are indole compounds with affinity for the 5-HT6 receptor, which have general formula (I) wherein, R1 is selected from the group consisting of H and C¿1-4?alkyl; R?2¿ is selected from the group consisting of H, C¿1-4?alkyl and benzyl; ----- represents a single or double bond; R?3¿ is selected from the group consisting of COR5 and SO¿2?R?5; R4a¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; R?4b¿ is selected from the group consisting of H, hydroxy, halo, C¿3-7?cycloalkyloxy, C1-4alkoxy, C1-4alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl; R?4c¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; R?4d¿ is selected from the group consisting of H, OH, halo, C¿1-4?alkyl and C1-4alkoxy; and R?5¿ is selected from the group consisting of phenyl, pyridyl, thienyl, quinolinyl and naphthyl which are optionally substituted with 1-4 substituents selected from C¿1-4?alkoxy, C1-4alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C1-4alkylcarbonyl, C1-4alkoxycarbonyl and C1-4alkylS-. Also described is the use of the compounds as pharmaceuticals to treat indications where inhibition of the 5-HT6 receptor is implicated, such as schizophrenia.
• Piperidine-indole compounds having 5-HT.sub.6 affinity
  申请人：Allelix Biopharmaceuticals Inc.

  公开号：US06133287A1

  公开（公告）日：2000-10-17

  Described herein are compounds with affinity for the 5-HT.sub.6 receptor, which have the general formula: wherein: R.sup.1 is selected from the group consisting of H and C.sub.1-4 alkyl; R.sup.2 is selected from the group consisting of H, C.sub.1-4 alkyl and benzyl; -- -- -- represents a single or double bond; R.sup.3 is selected from the group consisting of COR.sup.5 and SO.sub.2 R.sup.5 ; R.sup.4a is selected from the group consisting of H, OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; R.sup.4b is selected from the group consisting of H, hydroxy, halo, C.sub.3-7 cycloalkyloxy, C.sub.1-4 alkoxy, C.sub.1-4 alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl; R.sup.4c is selected from the group consisting of H, OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; R.sub.4d is selected from the group consisting of H, OH, halo, C.sub.1-4 alkyl and C.sub.1-4 alkoxy; and R.sup.5 is selected from the group consisting of phenyl, pyridyl, thienyl, quinolinyl and naphthyl which are optionally substituted with 1-4 substituents selected from C.sub.1-4 alkoxy, C.sub.1-4 alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C.sub.1-4 alkylcarbonyl, C.sub.1-4 alkoxycarbonyl and C.sub.1-4 alkylS--. Also described is the use of these compounds as pharmaceuticals to treat indications where inhibition of the 5-HT.sub.6 receptor is implicated, such as schizophrenia.

  本文描述了对5-HT.sub.6受体具有亲和力的化合物，其具有以下通式：其中：R.sup.1选自H和C.sub.1-4烷基的群组；R.sup.2选自H、C.sub.1-4烷基和苄基的群组；——表示单键或双键；R.sup.3选自COR.sup.5和SO.sub.2R.sup.5的群组；R.sup.4a选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sup.4b选自H、羟基、卤素、C.sub.3-7环烷氧基、C.sub.1-4烷氧基、C.sub.1-4烷基、苄氧基、苯氧基、三氟甲基、三氟甲氧基和乙烯基的群组；R.sup.4c选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sub.4d选自H、OH、卤素、C.sub.1-4烷基和C.sub.1-4烷氧基的群组；R.sup.5选自苯基、吡啶基、噻吩基、喹啉基和萘基，其中可以选用1-4个从C.sub.1-4烷氧基、C.sub.1-4烷基、卤素、硝基、三氟甲基、三氟甲氧基、1,2-亚甲二氧基、C.sub.1-4烷基羰基、C.sub.1-4烷氧基羰基和C.sub.1-4烷基S--中选择的取代基。还描述了这些化合物作为药物治疗5-HT.sub.6受体受到抑制的疾病，如精神分裂症的用途。